Overview

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Status:
Not yet recruiting

Trial end date:
2023-11-17

Target enrollment:

Participant gender:

Summary

This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel